Pin Therapeutics is focused on advancing innovative therapeutic platforms that leverage targeted protein degradation technologies. Their primary platforms include PinE3, which utilizes E3 ligase technology, and PinGLUE, which is based on molecular glue degraders. These platforms are designed to enhance the precision and efficacy of drug development by enabling the targeted degradation of specific proteins associated with various diseases, including solid and blood tumors. This approach aims to address the limitations of traditional small molecule drugs by providing a more effective means of modulating protein levels within cells.

The company’s pipeline reflects a commitment to developing therapies across multiple stages, from discovery to clinical development. Their research encompasses a range of indications, with a focus on solid tumors and blood cancers, utilizing both bifunctional degraders and selective molecular glue degraders. By integrating these advanced technologies, Pin Therapeutics aims to create novel treatment options that can significantly improve patient outcomes in oncology and other therapeutic areas.

South Korea

Pin Therapeutics - "Creating Therapeutic Products Degrading Disease-causing Proteins"​

Pin Therapeutics

Company Details